News >

Frontline Immunotherapy Firmly Established for Select Patients With NSCLC

Caroline Seymour
Published: Monday, Nov 11, 2019

Jamie E. Chaft, MD

Jamie E. Chaft, MD

The use of immunotherapy, either as monotherapy or in combination with chemotherapy, continues to raise the bar with regard to overall survival (OS) benefit in patients with newly diagnosed, advanced nonsquamous non–small cell lung cancer (NSCLC), said Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication